• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by MeiraGTx Holdings plc

    4/25/24 8:38:22 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MGTX alert in real time by email
    DEFA14A 1 tmb-20240425xdefa14a.htm DEFA14A

    ​

    ​

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934 (Amendment No.         )

    ​

    ​

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a-12

    ​

    ​

    MeiraGTx Holdings plc

    (Name of Registrant as Specified In Its Charter)

    ​

    ​

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    ​

    ​

    Payment of Filing Fee (Check all boxes that apply):

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

    ​

    ​


    GRAPHIC

    Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V48318-P11070 MEIRAGTX HOLDINGS PLC 450 EAST 29TH STREET, 14TH FLOOR NEW YORK, NY 10016 MEIRAGTX HOLDINGS PLC 2024 Annual Meeting Vote by June 5, 2024 11:59 PM ET You invested in MEIRAGTX HOLDINGS PLC and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on June 6, 2024. Vote Virtually at the Meeting* June 6, 2024 10:00 AM Eastern Time Virtually at: www.virtualshareholdermeeting.com/MGTX2024 Get informed before you vote View the Notice of Annual General Meeting, Proxy Statement and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 23, 2024. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

    GRAPHIC

    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V48319-P11070 1. Election of Directors For Nominees: 01) Alexandria Forbes, Ph.D. 02) Keith R. Harris, Ph.D. 03) Lord Mendoza 2. To approve, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers. For 3. To approve, on an advisory (non-binding) basis, the frequency of future advisory votes on the compensation of the Company’s named executive officers. 3 Years 4. To ratify, by ordinary resolution, the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. For NOTE: To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment thereof. THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

    Get the next $MGTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MGTX

    DatePrice TargetRatingAnalyst
    11/24/2025$20.00Buy
    H.C. Wainwright
    10/21/2025$29.00Strong Buy
    Raymond James
    7/31/2024$36.00Buy
    Chardan Capital Markets
    More analyst ratings

    $MGTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on MeiraGTx with a new price target

    H.C. Wainwright initiated coverage of MeiraGTx with a rating of Buy and set a new price target of $20.00

    11/24/25 8:18:26 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James initiated coverage on MeiraGTx with a new price target

    Raymond James initiated coverage of MeiraGTx with a rating of Strong Buy and set a new price target of $29.00

    10/21/25 7:21:05 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chardan Capital Markets resumed coverage on MeiraGTx with a new price target

    Chardan Capital Markets resumed coverage of MeiraGTx with a rating of Buy and set a new price target of $36.00

    7/31/24 6:30:53 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy

    BOSTON, Feb. 3, 2026 /PRNewswire/ -- ZipBio, a biotechnology company pioneering AI-driven protein therapeutics, announced an exclusive license agreement with MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company. Under the agreement, MeiraGTx will receive exclusive rights to ZipBio's first-in-class therapies for Geographic Atrophy, targeting the complement pathway. The licensing deal leverages the strengths of both companies, combining MeiraGTx's leadership in vector design, clinical development, and in-house manufacturing of genetic medicines, and ZipBio's expertise in de novo-designed protein therapeutics, developed using its COMPACT™ gener

    2/3/26 8:00:00 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference

    NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Graviton Bioscience Corporation, a clinical-stage biotechnology company developing selective ROCK2 inhibitors for metabolic, inflammatory, fibrotic, and central nervous system disorders, among other therapeutic indications, today announced that Samuel Waksal, Ph.D., Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore HealthCONx Conference. Details of the fireside chat are as follows: Tuesday, December 2, 2025 at 8:45am Eastern TimeThe fireside chat will provide an overview of Graviton's obesity research program and selective ROCK2 inhibitor development, highlighting: Target Biology. ROCK2 (Rho-associated coiled-coil

    11/20/25 3:00:00 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

    Entered into broad strategic collaboration with Eli Lilly and Company ("Lilly") in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company's AAV-AIPL1 program for treatment of one of the most severe inherited retinopathies, Leber congenital amaurosis 4 (LCA4) Released material under the Company's Specials license for a second rare pediatric ophthalmology condition caused by mutations in BBS10, with the prescribing physician treating the first patient during the quarter. The BBS10 program has been awarded Rare Pediatric Disease Designation (RPDD) LONDON and NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integr

    11/13/25 8:00:00 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Perceptive Advisors Llc bought $5,000,000 worth of Ordinary Shares (1,250,000 units at $4.00) (SEC Form 4)

    4 - MeiraGTx Holdings plc (0001735438) (Issuer)

    8/14/24 6:54:38 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by MeiraGTx Holdings plc

    SCHEDULE 13D/A - MeiraGTx Holdings plc (0001735438) (Subject)

    1/2/26 4:20:05 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MeiraGTx Holdings plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - MeiraGTx Holdings plc (0001735438) (Filer)

    1/2/26 8:02:20 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by MeiraGTx Holdings plc

    SCHEDULE 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

    11/13/25 9:05:15 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF MEDICAL OFFICER Zeldin Robert K converted options into 35,000 units of Ordinary Shares and covered exercise/tax liability with 13,951 units of Ordinary Shares, increasing direct ownership by 14% to 168,340 units (SEC Form 4)

    4 - MeiraGTx Holdings plc (0001735438) (Issuer)

    1/21/26 9:25:42 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GENERAL COUNSEL AND SECRETARY Wollin Robert J converted options into 50,000 units of Ordinary Shares and covered exercise/tax liability with 27,206 units of Ordinary Shares, increasing direct ownership by 78% to 52,076 units (SEC Form 4)

    4 - MeiraGTx Holdings plc (0001735438) (Issuer)

    1/21/26 9:21:24 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF DEV. OFFICER Naylor Stuart covered exercise/tax liability with 35,250 units of Ordinary Shares and converted options into 75,000 units of Ordinary Shares, increasing direct ownership by 6% to 682,916 units (SEC Form 4)

    4 - MeiraGTx Holdings plc (0001735438) (Issuer)

    1/21/26 9:15:29 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    Leadership Updates

    Live Leadership Updates

    View All

    Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

    ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

    11/24/24 7:27:00 PM ET
    $LIAN
    $MGTX
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Landsdowne Labs Names Bryan Laulicht CEO

    Company cofounder and CTO to lead button battery safety tech company toward commercialization The Directors of Landsdowne Labs, LLC, are pleased to announce the appointment of Bryan Laulicht to Chief Executive Officer. Laulicht, a company cofounder, has served as Lansdowne's Chief Technology Officer since the company's formation in 2017. He has also co-founded and served in leadership positions at two other companies focused on applying biophysics and bioengineering approaches to fulfilling unmet medical and safety needs. Both of those companies have been acquired for a combined total greater than $500M. Lansdowne's technology, applied to small, coin-like "button" batteries, is design

    6/13/23 9:05:00 AM ET
    $MGTX
    $AMAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Pharmaceuticals

    MeiraGTx Appoints Debra Yu, MD to Board of Directors

    LONDON and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Dr. Debra Yu to its Board of Directors. Dr. Yu currently serves as President and Chief Strategy Officer of LianBio, and previously served as LianBio's President and Chief Business Officer. Dr. Yu has more than 30 years of healthcare industry experience in business development, alliance management, investment banking and capital markets. She has held senior positions at Pfizer in its Worldwide Business Development organization and Labrador Advisors, LLC, where she advised numerous partnerships and licen

    4/27/22 8:00:00 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    Financials

    Live finance-specific insights

    View All

    MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

    Clinically meaningful improvements in xerostomia symptoms measured by two different xerostomia PROs demonstrated across both unilaterally and bilaterally treated cohorts at 12 monthsIncreases in whole saliva flow rates observed post-treatment, providing objective evidence of biological activity, reaching the normal range in bilaterally treated participants by 2 months and persisting through the Month 12 assessmentAcross assessments, greater improvements observed in bilaterally treated participants compared to those treated unilaterally Early long-term follow-up data suggest durability of improvement to at least 3 years post-treatmentAAV2-hAQP1 appears safe and well tolerated at each dose te

    6/27/23 7:30:00 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company's Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27, 2023

    LONDON and NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to present an update on the Company's AAV-hAQP1 clinical program for the treatment of grade 2/3 radiation-induced xerostomia (RIX) on Tuesday, June 27, 2023, at 8:00 a.m. ET. The presentation will include: 1) Data from the completed Phase 1 AQUAx clinical study for the 24 patients treated with AAV-hAQP1 in the unilateral and bilateral cohorts: Safety and tolerability12-month data for PRO assessments of xerostomia symptoms in the unilateral cohorts (n=12)12-month data for

    6/22/23 4:01:00 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

    Clinically meaningful improvements in xerostomia symptoms and disease burden reported in patient reported outcome (PRO) measures in both unilateral and bilateral cohortsIncreases in whole saliva flow rates were seen in both unilateral and bilateral cohorts Overall degree of improvement was greater in bilateral compared to unilateral cohorts AAV2-hAQP1 appears safe and well tolerated at each dose tested Webcast and conference call to be held today, December 13, 2022, at 8:00 a.m. ET LONDON and NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive clinical data from the ongoin

    12/13/22 7:30:00 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MGTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MeiraGTx Holdings plc

    SC 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

    11/12/24 9:40:33 AM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by MeiraGTx Holdings plc

    SC 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

    10/18/24 4:47:58 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by MeiraGTx Holdings plc

    SC 13D/A - MeiraGTx Holdings plc (0001735438) (Subject)

    8/14/24 7:21:27 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care